دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Women in science: inspiring future generations
doi : 10.1016/S2213-8587(24)00038-X
Volume 12, Issue 3, March 2024, Page 149
Glucagon—a new player in weight management therapeutics?
Stephen C Bain a, David M Williams a
doi : 10.1016/S2213-8587(24)00029-9
Volume 12, Issue 3, March 2024, Pages 150-151
An anti-PCSK9 pill a day to keep cholesterol away: next steps?
Gerald F Watts a
doi : 10.1016/S2213-8587(23)00358-3
Volume 12, Issue 3, March 2024, Pages 151-153
GLP-1 analogue therapy for obesity in people from Asia
Bernard Khoo a, Tricia M-M Tan b
doi : 10.1016/S2213-8587(24)00031-7
Volume 12, Issue 3, March 2024, Pages 153-154
Living between two worlds: lessons for community involvement
Ashley H Ng a b, Matthew Quigley c, Tim Benson d, Lauren Cusack e, Rachel Hicks f, Ben Nash g h, Meaghan Read i, Renza Scibilia j, Cheryl Steele k, Leon Tribe l, Elizabeth Holmes-Truscott m n o
doi : 10.1016/S2213-8587(24)00032-9
Volume 12, Issue 3, March 2024, Pages 155-157
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023
doi : 10.1016/S2213-8587(24)00030-5
Volume 12, Issue 3, March 2024, Pages e13-e15
Milestone achievement for global access to blood glucose meters and test strips
Emma Klatman a, Beatrice Vetter b, Cathy Haldane b, Graham Ogle a
doi : 10.1016/S2213-8587(24)00037-8
Volume 12, Issue 3, March 2024, Pages 158-159
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria
Talha Burki
doi : 10.1016/S2213-8587(24)00034-2
Volume 12, Issue 3, March 2024, Pages 160-161
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50
doi : 10.1016/S2213-8587(24)00033-0
Volume 12, Issue 3, March 2024, Page e16
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Prof Carel W le Roux MD a, Oren Steen MD b, Kathryn J Lucas MD c, Elena Startseva MD d, Anna Unseld MSc e, Anita M Hennige MD f
doi : 10.1016/S2213-8587(23)00356-X
Volume 12, Issue 3, March 2024, Pages 162-173
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Michael J Koren MD a, Olivier Descamps MD b, Yoshiki Hata MD c, Ellen Margo Hengeveld MD d, Prof G Kees Hovingh MD d e, Prof Ignatios Ikonomidis PhD f, Maria D Radu Juul Jensen MD d, Irene Hedelund Langbakke MD d, Prof Fabrice M A C Martens MD g †, Anette Luther Søndergaard MSc d, Prof Adam Witkowski MD h, Prof Wolfgang Koenig MD i j
doi : 10.1016/S2213-8587(23)00325-X
Volume 12, Issue 3, March 2024, Pages 174-183
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Prof Yiming Mu MD a, Xiaolei Bao PhD b, Freddy G Eliaschewitz MD c, Morten Rix Hansen MD d, Bom Taeck Kim MD e, Anna Koroleva MD d, Ronald C W Ma FRCP f, Tao Yang MD g, Ning Zu MD b, Ming Liu MD h, STEP 7 Study Group
doi : 10.1016/S2213-8587(23)00388-1
Volume 12, Issue 3, March 2024, Pages 184-195
Air pollution exposure and cardiometabolic risk
Prof Sanjay Rajagopalan MD a, Prof Robert D Brook MD b, Pedro R V O Salerno MD a, Brendan Bourges-Sevenier BS a, Prof Philip Landrigan MD c d, Prof Mark J Nieuwenhuijsen PhD e, Prof Thomas Munzel MD f g, Salil V Deo MD h, Sadeer Al-Kindi MD i
doi : 10.1016/S2213-8587(23)00361-3
Volume 12, Issue 3, March 2024, Pages 196-208
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
Prof Ken K Y Ho MD a, Prof Maria Fleseriu MD b, Prof John Wass MD c, Prof Laurence Katznelson MD d, Prof Gerald Raverot MD e, Prof Andrew S Little MD f, Prof Justo P Castaño PhD g, Prof Martin Reincke MD h, Prof M Beatriz Lopes MD i, Prof Ursula B Kaiser MD j, Prof Philippe Chanson MD k, Prof Mônica Gadelha MD l, Prof Shlomo Melmed MBChB m
doi : 10.1016/S2213-8587(23)00382-0
Volume 12, Issue 3, March 2024, Pages 209-214
